Long-term results of children diagnosed with idiopathic nephrotic syndrome; single center experience;İdiyopatik nefrotik sendrom tanılı çocukların uzun dönem sonuçları; tek merkez deneyimi

Turk Pediatri Arsivi

Volumn 50, Issue 1, 2015, Pages 37-44

  Övünç Hacıhamdioğlu, Duygu ^a   Kalman, Süleyman ^b   Gök, Faysal ^b  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Child; Course; Nephrotic syndrome; Treatment

Indexed keywords

ARTICLE; BIOPSY; BONE DENSITY; CATARACT; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; INFANT; KIDNEY DISEASE; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; NEPHROTIC SYNDROME; RISK; SHORT STATURE;

EID: 84926675334     PISSN: 13060015     EISSN: 13086278     Source Type: Journal    
DOI: 10.5152/tpa.2015.2086     Document Type: Article

References (43)

1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003; 362: 629-39.[CrossRef ]
2. International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: clinical significance of histopath-ologi c variants of minimal change and of diffuse mesangial hyper-cellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981; 20: 765-71.[CrossRef ]
3. Mekahli D, Liutkus A, Ranchin B, et al. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 2009; 24: 1525-32.[CrossRef ]
4. Paik KH, Lee BH, Cho HY, et al. Primary focal segmental glomerular sclerosis in children: clinical course and prognosis. Pediatr Nephrol 2007; 22: 389-95.[CrossRef ]
5. Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001; 16: 271-82.[CrossRef ]
6. Niaudet P, Boyer O. Idiopathic nephrotic syndrome in chil-dren: Clinical aspects. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, (eds). Pediatric Nephrology. 6th ed. Berlin Heidelberg: Springer-Verlag, 2009: 667-9.[CrossRef ]
7. International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A Report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98: 561-4.[CrossRef ]
8. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-76.[CrossRef ]
9. Bianchi ML, Baim S, Bishop NJ, et al. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol 2010; 25: 37-47.[CrossRef ]
10. International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13: 159-65.[CrossRef ]
11. Karagüzel G, Mocan H, Aynacı M, ve ark. Doğu Karadeniz bölgesinde çocukluk çağında nefrotik sendrom. XXXVIII. Milli Pediatri Kongresi, Trabzon, 1994: 31.
12. Öner A, Demircan G, Bülbül M. Pediatrik nefrotik sendrom vakalarının retrospektif olarak incelemesi. XI. Ulusal Böbrek Hastalıkları, Dializ ve Transplantasyon Kongresi, Samsun. 1994: 98.
13. Van A, İşlek İ, Dağdemir A, Koçak H, Küçükkodük Ş. Çocukluk çağı nefrotik sendromu: 230 olgunun değerlendirilmesi. OMÜ Tıp Dergisi 2001; 18: 71-9.
14. Peru H, Karagöl C, Elmacı AM, Kara F. Nefrotik Sendromlu 141 olgunun retrospektif analizi. Selçuk Tıp Dergisi 2008; 25: 23-9.
15. Toyabe S, Nakamizo M, Uchiyama M, Akazawa K. Circannual variation in the onset and relapse of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2005; 20: 470-3.[CrossRef ]
16. Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch Dis Child 2008; 93: 226-8.[CrossRef ]
17. Lombel RM, Gipson DS, Hodson E. Kidney disease: Improving global outcomes. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013; 28: 415-26.[CrossRef ]
18. Yavaşcan Ö, Aksu N, Erdoğan H, ve ark. Çocuklarda böbrek biyopsi sonuçlarının değerlendirilmesi: On bir yıllık süre. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 2005; 14: 195-201.
19. Büscher AK, Kranz B, Büscher R, et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2010; 5: 2075-84.[CrossRef ]
20. Lombel RM, Hodson EM, Gipson DS. Kidney disease: Improving global outcomes. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 2013; 28: 409-14.[CrossRef ]
21. Ng JS, Wong W, Law RW, Hui J, Wong EN, Lam DS. Ocular complications of paediatric patients with nephrotic syndrome. Clin Experiment Ophthalmol 2001; 29: 239-43.[CrossRef ]
22. Brocklebank JT, Harcourt RB, Meadow SR. Corticosteroid-induced cataracts in idiopathic nephrotic syndrome. Arch Dis Child 1982; 57: 30-4.
23. Sumboonnanonda A, Chongchate N, Suntornpoch V, Pattaragarn A, Supavekin S. Difficult-to-treat nephrotic syndrome: management and outcome. J Med Assoc Thai 2005; 88: 142-8.
24. Al Salloum AA, Muthanna A, Bassrawi R, et al. Long-term outcome of the difficult nephrotic syndrome in children. Saudi J Kidney Dis Transpl 2012; 23: 965-72.[CrossRef ]
25. Simmonds J, Grundy N, Trompeter R, Tullus K. Longterm steroid treatment and growth: a study in steroiddependent nephrotic syndrome. Arch Dis Child 2010; 95: 146-9.[CrossRef ]
26. Fleısher DS, McCrory WW, Rapoport M. The effects of intermittent doses of adrenocortical steroids on the statural growth of nephrotic children. J Pediatr 1960; 57: 192-8.[CrossRef ]
27. Simon D. Management of growth retardation in juvenile idiopathic arthritis. Horm Res 2007; 68: 122-5.[CrossRef ]
28. Mehls O, Tönshoff B, Kovàcs G, Mayer C, Schurek J, Oh J. Interaction between glucocorticoids and growth hormone. Acta Paediatr Suppl 1993; 388: 77-82. [+]
29. Varma S. Growth hormon treatment for children on chronic corticosteroids. AAP Grand Rounds 2007; 18; 47.[CrossRef ]
30. Tönshoff B, Haffner D, Mehls O, et al. Efficacy and safety of growth hormone treatment in short children with allografts: three years experience. Members of the German Study Group for Growth Hormone Treatment in Children with Renal Allografts. Kidney Int 1993; 44: 199-207.[CrossRef ]
31. Hokken-Koelega AC, Stijnen T, de Ridder MA, et al. Growth hormone treatment in growth-retarded adolescents after renal transplant. Lancet 1994; 343: 1313-7.[CrossRef ]
32. Zhou X, Loke KY, Pillai CC, How HK, Yap HK, Lee KO. IGFs and IGF-binding proteins in short children with steroid-dependent nephrotic syndrome on chronic glucocorticoids: changes with 1 year exogenous GH. Eur J Endocrinol 2001; 144: 237-43.[CrossRef ]
33. Sun L, Chen D, Zhao X, Xu C, Mei C. Successful treatment of dwarfism secondary to long-term steroid therapy in steroid-dependent nephrotic syndrome. Intern Med 2010; 49: 1417-21.[CrossRef ]
34. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-82.[CrossRef ]
35. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-87.[CrossRef ]
36. Kyrieleis HAC, Löwik MM, Pronk I, et al. Long-term outcome of biopsy-proven, frequently relapsing minimalchange nephrotic syndrome in children. Clin J Am Soc Nephrol 2009; 4: 1593-600.[CrossRef ]
37. van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18: 913-8.[CrossRef ]
38. Ikeda S, Morishita Y, Tsutsumi H, et al. Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs. Bone 2003; 33: 779-87.[CrossRef ]
39. Bak M, Serdaroglu E, Guclu R. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome. Pediatr Nephrol 2006; 21: 350-4.[CrossRef ]
40. Zaniew M, Jarmoliński T. Vitamin D status and bone density in steroid-treated children with glomerulopathies: effect of cholecalciferol and calcium supplementation. Adv Med Sci 2012; 57: 88-93.[CrossRef ]
41. Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 2007; 49: 592-7.[CrossRef ]
42. Azib S, Macher MA, Kwon T, et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011; 26: 927-32.[CrossRef ]
43. Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin Nephrol 1991; 35: S31-6.